Thursday, 19 May 2011

Versant Analyst Highlights Neptune on BNN

Neptune Technologies & Bioressources
Basic Shares: 48.2 million
Fully diluted: 53.9 million


In the wake of Versant analyst Doug Loe's much touted initiating coverage report on Neptune Technologies and its 60%-0wned subsidiary Acasti Pharma, Mr. Loe appeared on BNN today to further explain why he is recommending a "Buy" of Neptune & Acasti shares.

To view the full clip, please click here.